Previous 10 | Next 10 |
AtriCure Inc. (ATRC) Q4 2021 Results Conference Call February 15, 2022 4:30 PM ET Company Participants Marissa Bych - Gilmartin Group Michael Carrel - President, CEO Angela Wirick - CFO Conference Call Participants David Saxon - Needham Robbie Marcus - JPMorgan Matthew O'Brien - Piper Sandler...
AtriCure press release (NASDAQ:ATRC): Q4 Non-GAAP EPS of -$0.30 beats by $0.01. Revenue of $73.22M (+26.8% Y/Y) beats by $0.56M. For further details see: AtriCure Non-GAAP EPS of -$0.30 beats by $0.01, revenue of $73.22M beats by $0.56M
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2021 and full year 2021 financial results. ...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today published its inaugural Environmental, Social and Governance (ESG) report hi...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming 11 th Annual SVB Leerink Global Healthcare Conference...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2021 financ...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, announced preliminary financial results for the fourth quarter and full year 2021...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming 40 th Annual J.P. Morgan Healthcare Conference. A...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Piper Sandler 33 rd Annual Virtual Healthcare Confere...
Image source: The Motley Fool. AtriCure, inc (NASDAQ: ATRC) Q3 2021 Earnings Call Nov 3, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: AtriCure, inc (ATRC) Q3 2021 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
Worldwide revenue of $116.3 million – an increase of 15.2% year over year Positive cash flow generation of $8.1 million in second quarter 2024 AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), l...
CFSB Bancorp Inc. (CFSB) is expected to report for Q4 2024 Big 5 Sporting Goods Corporation (BGFV) is expected to report $-0.48 for Q2 2024 Canadian Pacific Kansas City Limited (CP) is expected to report $0.74 for Q2 2024 Captivision Inc. (CAPT) is expected to report for quarter end 2...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Canaccord Genuity 44th...